Does Analyst Value Call Change The Bull Case For SCOR (ENXTPA:SCR)?

• Analyst coverage has recently highlighted SCOR as trading below estimated fair value, with attention on its capital strength and Life & Health pipeline, bringing its valuation profile back into focus for investors.
• The emphasis on SCOR's robust capital position and data driven Life & Health portfolio underlines how underwriting choices and product mix shape its risk capacity more than headline ratings alone.
• We will now look at how SCOR's investment narrative might shift as renewed focus on its capital strength feeds into expectations.

Scan beyond SCOR and size up other potential value ideas by reviewing the hand picked 173 high quality undervalued stocks that share a focus on pricing discipline and balance sheet strength.

SCOR Investment Narrative Recap

To own SCOR, you need to be comfortable with a reinsurer that leans heavily on capital strength, disciplined underwriting and a data driven Life & Health engine rather than headline premium growth. The short term swing factor is whether management can keep margins and catastrophe experience in check while 2025 insurance revenue guidance stays flattish.

The biggest risk right now sits in that mix of higher North American hurricane exposure, rising competition and ongoing legal disputes with Covéa. Recent attention on valuation and capital strength does not change those operational pressure points much. It mainly spotlights how much room SCOR has to absorb shocks.

The recent Zacks mention ties most closely to SCOR being flagged as good value and trading below some fair value estimates. That intersects directly with the firm’s solid solvency ratio and the Life & Health pipeline, which are central to how much risk it can prudently take on without stretching the balance sheet.

For you as an investor, the useful angle in that coverage is how it reframes the trade off. On one side are earnings that have grown faster than the wider insurance sector and a low P/E. On the other side sit flattish near term revenue expectations, higher catastrophe exposure and currency and legal risks that could unsettle that picture.

SCOR Consensus Forecasts At A Glance

SCOR's current analyst framework ties the story to relatively flat top line expectations and a moderate uplift in profitability rather than bold growth assumptions.

Consensus forecasts point to revenue declining by about 1.4% per year over the next three years, even as analysts expect profit margins to edge up from 4.9% today to 5.3% by 2029.

Earnings today sit at €823.0 million and the same group of forecasters projects net profit of €863.6 million by 2029, with a wide spread between the most optimistic estimate of €956.5 million and the most cautious at €736.9 million.

SCOR's narrative projects €16.2b revenue and €863.6 million earnings by 2029. This involves revenue falling by 1.4% per year and an earnings increase of about €40.6 million from €823.0 million today.

On these assumptions, the stock would trade on a P/E of 9.0x 2029 earnings, compared with about 7.4x on current earnings and against an industry reference point of 11.9x for the wider GB insurance peer group.

Analysts are also building in a very small reduction in share count of roughly 0.05% per year over the next three years, so per share numbers depend more on the profit line than on buybacks.

To tie these moving parts together, the consensus view uses a discount rate of about 6.5% and lands on a shared price target near €35.97, only 4.7% higher than the current price of €34.3. This frames SCOR as roughly in line with those modelled expectations rather than a clear mispricing.

Uncover why SCOR's fair value indicates a 13% potential upside to its current price that could narrow quickly.

Exploring Other Perspectives

Two fair value views from the Simply Wall St Community span roughly €35.97 to €96.07 for SCOR, so private investors are clearly split on how to price its capital strength and Life & Health pipeline. When you also consider flat 2025 revenue guidance, rising competition and higher hurricane exposure, you get sharply different expectations for future resilience.

Explore another SCOR fair value estimate, including one that suggests it could be worth just €35.97.

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and research.

• A great starting point for your SCOR research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for SCOR. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate SCOR's overall financial health at a glance.

Looking For More Ideas Beyond SCOR?

If the SCOR story has sharpened your thinking on valuation, risk and balance sheet strength, it can be useful to line it up against a wider watchlist built with clear filters and consistent rules.

• If you want higher income potential with an eye on resilience, scan through 223 dividend fortresses that match a minimum 5% yield with a focus on durability.
• For investors who care most about financial robustness, build a watchlist from the list of solid balance sheet and fundamentals (204 results) to compare SCOR with peers that also prioritise strong fundamentals.
• If you prefer to hunt for earlier stage opportunities with room to mature, review the 618 high quality undiscovered gems that pair quality metrics with lower current market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com